Interleukin‐1 blockade treatment decreasing cardiovascular risk - Zheng, Zi‐Heng; Zeng, Xun; Nie, Xiao‐Ying; Cheng, Yun‐Jiu; Liu, Jun; Lin, Xiao‐Xiong; Yao, Hao; Ji, Cheng‐Cheng; Chen, Xu‐Miao; Jun, Fan; Wu, Su‐Hua (Clinical cardiology (Mahwah, N.J.), 2019)
Keywords: anakinra; Anti-Inflammatory Agents - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Antirheumatic Agents - therapeutic use; canakinumab; Cardiovascular Diseases - blood; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - epidemiology; cardiovascular events; Cause of Death; Clinical Investigations; Global Health; Humans; Incidence; Interleukin 1 Receptor Antagonist Protein - therapeutic use; Interleukin-1 - antagonists & inhibitors; Interleukin-1 - blood; Interleukin‐1 blockade; meta‐analysis; Recombinant Fusion Proteins - therapeutic use; Risk Factors; cardiovascular events; meta-analysis; anakinra; canakinumab; Interleukin-1 blockade